ProfoundBio
Signal active
Organization
Contact Information
Overview
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages.
About
Industries
Biotechnology, Therapeutics, Oncology
Founded
2018
Employees
51-100
Headquarters locations
United States, North America
Social
N/A
Profile Resume
ProfoundBio headquartered in United States, North America, operates in the Biotechnology, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $11.9B in funding across 48 round(s). With a team of 51-100 employees, ProfoundBio is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - ProfoundBio, raised $112.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
14
Lead Investors
0
Total Funding Amount
$247.0M
Details
4
ProfoundBio has raised a total of $247.0M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 55.0M | ||
| 2021 | Seed | 10.0M | ||
| 2022 | Early Stage Venture | 70.0M | ||
| 2024 | Early Stage Venture | 112.0M |
Investors
ProfoundBio is funded by 39 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Ally Bridge Group | - | FUNDING ROUND - Ally Bridge Group | 112.0M |
| Fei Chen | - | FUNDING ROUND - Fei Chen | 112.0M |
| ProfoundBio | - | FUNDING ROUND - ProfoundBio | 112.0M |
| Lilly Asia Ventures | - | FUNDING ROUND - Lilly Asia Ventures | 112.0M |
Recent Activity
There is no recent news or activity for this profile.